Protekt Therapeutics

ProteKt Therapeutics is a biotechnology company pioneering the development of novel, highly selective inhibitors of Protein Kinase R (PKR) for the treatment of neurodegenerative and neuroinflammatory diseases. PKR is a key regulator of cellular stress responses, and its activation is increasingly recognized as a central contributor to the pathology of conditions such as Alzheimer's disease, ALS, and other CNS disorders. Our lead compounds target PKR upstream of neurodegeneration, offering a mechanism-based, disease-modifying approach. Backed by strong preclinical efficacy and safety data, ProteKt’s therapeutic strategy is designed to reduce neuronal loss, dampen chronic inflammation, and improve functional outcomes.